935700 Stock Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 4/6 |
| Dividends | 3/6 |
Gilead Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.48 |
| 52 Week High | US$82.53 |
| 52 Week Low | US$66.91 |
| Beta | 0.39 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 10.45% |
| 3 Year Change | -8.69% |
| 5 Year Change | -11.64% |
| Change since IPO | -36.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| 935700 | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -0.6% |
| 1Y | 10.5% | 14.1% | -3.9% |
Return vs Industry: 000935700 exceeded the Swiss Biotechs industry which returned -24.8% over the past year.
Return vs Market: 000935700 exceeded the Swiss Market which returned -0.9% over the past year.
Price Volatility
| 935700 volatility | |
|---|---|
| 935700 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 7.3% |
| 10% least volatile stocks in CH Market | 1.9% |
Stable Share Price: 000935700 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 000935700's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 17,000 | Dan O'Day | www.gilead.com |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections.
Gilead Sciences, Inc. Fundamentals Summary
| 935700 fundamental statistics | |
|---|---|
| Market cap | CHF86.31b |
| Earnings (TTM) | CHF5.03b |
| Revenue (TTM) | CHF25.11b |
17.2x
P/E Ratio3.4x
P/S RatioIs 935700 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 935700 income statement (TTM) | |
|---|---|
| Revenue | US$27.38b |
| Cost of Revenue | US$5.63b |
| Gross Profit | US$21.75b |
| Other Expenses | US$16.26b |
| Earnings | US$5.48b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.40 |
| Gross Margin | 79.42% |
| Net Profit Margin | 20.03% |
| Debt/Equity Ratio | 119.7% |
How did 935700 perform over the long term?
See historical performance and comparison